# Filing Detail

Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001104659-26-065876
Filing Date
2026-05-26
Accepted
2026-05-26 06:00:54
Documents
6

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFM14A | tm2612585-2_defm14a.htm | DEFM14A | 2130417
2 | GRAPHIC | lg_cumberland-4clr.jpg | GRAPHIC | 15463
3 | GRAPHIC | lg_velocity-4c.jpg | GRAPHIC | 6000
4 | GRAPHIC | sg_velocity-bw.jpg | GRAPHIC | 6676
5 | GRAPHIC | px_26cumberlandproxy1pg01-bw.jpg | GRAPHIC | 357820
6 | GRAPHIC | px_26cumberlandproxy1pg02-bw.jpg | GRAPHIC | 327341
| Complete submission text file | 0001104659-26-065876.txt |  | 3114476

Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-33637 | Film No.: 261015778
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)